00:49 , Aug 17, 2019 |  BioCentury  |  Emerging Company Profile

Impact casting a wide synthetic lethality net

After laying the foundation with its PARP inhibitor, Impact plans to build a comprehensive synthetic lethality pipeline across known DNA damage repair targets and new ones outside of DDR to address a wider range of...
22:35 , Aug 5, 2019 |  BC Extra  |  Clinical News

Bladder cancer data gives Tecentriq another first-line win

With more positive data in first-line bladder cancer, Roche's Tecentriq could become the leading immunotherapy agent for the indication. An interim analysis of the 1,213-patient Phase III IMvigor-130 trial showed Tecentriq atezolizumab plus chemotherapy met...
22:54 , Aug 1, 2019 |  BC Innovations  |  Product Development

NeuBase takes antisense oligos to more targets in more places

Newcomer NeuBase Therapeutics is re-engineering antisense oligos to access a broader range of targets, while simultaneously solving the modality’s dosing and delivery issues. With three approvals since the start of 2016, antisense oligonucleotides (ASOs) have...
22:17 , Jul 24, 2019 |  BC Innovations  |  Translation in Brief

Unraveling checkpoint responses in PD-L1-negative cancers

A new study from City of Hope offers a long-sought explanation for why some patients lacking PD-L1 expression on their tumors respond to antibodies against the target, and uncovers a way to boost NK cell...
22:39 , Jul 9, 2019 |  BC Extra  |  Company News

July 9 Company Quick Takes: Celgene, Nimbus expand deal; plus Gilead-Lyndra, Darzalex and more

Celgene gets option for Nimbus' HPK1 program  Celgene Corp. (NASDAQ:CELG) expanded its partnership with Nimbus Therapeutics LLC (Cambridge, Mass.) to include an option for the latter's HPK1 inhibitor to treat cancer, which Celgene can exercise...
23:56 , Jul 8, 2019 |  BC Extra  |  Financial News

On heels of series C extension, RAPT Therapeutics files for IPO

Just weeks after topping off its series C round, Flexus spinout RAPT Therapeutics Inc. (South San Francisco, Calif.) has filed to raise up to $86.3 million in an IPO on NASDAQ underwritten by BofA Merrill...
01:37 , Jun 28, 2019 |  BC Innovations  |  Product Development

How Array stayed alive long enough to grow up

Array’s 21-year journey as an independent platform company, culminating in an $11.4 billion buyout, required shifting focus from research to development and back again. The acquisition sends a message that developing focused expertise and sticking...
22:41 , Jun 20, 2019 |  BC Innovations  |  Targets & Mechanisms

Moving beyond the active site: why allostery is newly in fashion

A new crop of companies is creating tools to systematize development of allosteric protein inhibitors, finally moving industry beyond the one-off compounds that have been found by accident. Allosteric pockets on proteins have long been...
01:27 , Jun 18, 2019 |  BC Innovations  |  Distillery Therapeutics

CAMKK2 identified as target for breast cancer

DISEASE CATEGORY: Cancer INDICATION: Breast cancer Inhibition of CAMKK2 could treat breast cancer. In patients, high tumor expression of CAMKK2 was associated with triple-negative breast cancer (TNBC) and low expression was associated with the less...
00:43 , Jun 18, 2019 |  BC Extra  |  Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

VBI falls with HBV vaccine miss on secondary endpoint  VBI Vaccines Inc. (NASDAQ:VBIV) sank $1.24 (66%) to $0.65 Monday after reporting that two doses of Sci-B-Vac failed to show non-inferior seroprotection at day 168 vs....